Literature DB >> 6988222

Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension.

M Thibonnier, F Bonnet, P Corvol.   

Abstract

The magnitude and duration of the antihypertensive effect of nifedipine were studied in 7 cases of moderate essential hypertension. In a double-blind crossover study, nifedipine 10 mg or a placebo were administered sublingually 4 times a day for 2 days, and the results were compared. Each dose of nifedipine reduced systolic and diastolic blood pressure by 14% both in the supine and upright positions. The antihypertensive action lasted for about 3 h and it was not cumulative. The reduction in blood pressure was associated with a temporary increase in heart rate. Administration of nifedipine 10 mg did not significantly raise plasma renin activity or plasma aldosterone. The drug was well tolerated and no side effects were detected.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6988222     DOI: 10.1007/BF00561894

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  [Radioimmunoassays of aldosterone and plasma renin activity. Application to the diagnosis of primary aldosteronism].

Authors:  P Corvol; J Ménard; X Bertagna
Journal:  Ann Endocrinol (Paris)       Date:  1973 Jan-Feb       Impact factor: 2.478

2.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

3.  Nifedipine, a new antihypertensive with rapid action.

Authors:  M Guazzi; M T Olivari; A Polese; C Fiorentini; F Magrini; P Moruzzi
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

4.  Haemodynamic effects of a calcium antagonistic agent (nifedipine) in hypertension: therapeutic implications.

Authors:  C Bartorelli; F Magrini; P Moruzzi; M T Olivari; A Polese; C Fiorentini; M Guazzi
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

5.  Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

Authors:  K Aoki; T Yoshida; S Kato; K Tazumi; I Sato
Journal:  Jpn Heart J       Date:  1976-07

6.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

  6 in total
  17 in total

1.  Pharmacokinetics of nifedipine derived from a new retard tablet formulation.

Authors:  A Avgerinos; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine.

Authors:  V Challenor; D G Waller; B S Gruchy; A G Renwick; C F George; E T McMurdo; J McEwen
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

6.  Influence of nicardipine on blood pressure, renal function and plasma aldosterone in normotensive volunteers.

Authors:  B A van Schaik; R J Hene; G G Geyskes
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

Authors:  H E Sluiter; F T Huysmans; T A Thien; R A Koene
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Nifedipine serum concentration; effects upon blood pressure and heart rate in normotensive volunteers.

Authors:  T Nakashima; M Inoki; Y Nakanishi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

10.  Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.

Authors:  K P Ohman; L Weiner; H von Schenck; B E Karlberg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.